Related Experiment Video
Updated: Feb 28, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Suppressing the Aberrant Transcriptional Functionality of EWS::FLI1 Oncoprotein by Designer polyQ Fusions with Its
Heng-Tong Duan1,2, Xiang-Le Zhang1,2, Lei-Lei Jiang1
1Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
Abstract:
Background/Objectives: The oncoprotein EWS::FLI1 is a chimeric transcription factor that aberrantly brings transcriptional deregulation relevant to Ewing sarcoma. It is also regarded as a therapeutic target for suppressing oncogenic progression, but the inhibition and clearance of the EWS::FLI1 oncoprotein remain a challenge. Methods: We apply a polyglutamine (polyQ) fusion strategy to directly target EWS::FLI1 in suppression of its transcriptional malfunction in A673 cells derived from Ewing sarcoma. Based on the template of the N-terminal fragment of polyQ-expanded ataxin-7 (Atx793Q-N172) and the homologous peptides of EWS::FLI1, we have designed and constructed three polyQ fusion proteins, namely Atx793Q-N172-SYGQ1, Atx793Q-N172-SYGQ2, and Atx793Q-N172-LCD. Results: Supernatant/pellet fractionation and immunofluorescence imaging reveal that the polyQ fusion proteins co-precipitate and co-localize with EWS::FLI1 in A673 cells, indicating that the polyQ fusions we have designed can sequester endogenous EWS::FLI1 into insoluble aggregates and reduce its cellular availability. Moreover, these polyQ fusions, especially Atx793Q-N172-LCD, alter the expression of EWS::FLI1 downstream genes, with an increase in P21 (CDKN1A) and a decrease in c-Myc. Conclusions: These results demonstrate that the engineered polyQ fusions entrap endogenous EWS::FLI1 protein into aggregates and reduce its soluble fraction in Ewing sarcoma cells. This study provides an alternative potential for treating Ewing sarcoma and other tumors by directly targeting the oncogenic proteins in the future.
Insights
Researchers developed polyglutamine (polyQ) fusions to target the EWS::FLI1 oncoprotein in Ewing sarcoma. These fusions sequester EWS::FLI1, reducing its availability and altering downstream gene expression, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ewing sarcoma is driven by the EWS::FLI1 oncoprotein, a chimeric transcription factor causing aberrant gene regulation.
- Targeting EWS::FLI1 is crucial for suppressing oncogenic progression, but its inhibition and clearance present significant challenges.
- Current therapeutic strategies require novel approaches to directly address EWS::FLI1's oncogenic functions.
Purpose of the Study:
- To investigate the efficacy of a polyglutamine (polyQ) fusion strategy for directly targeting and suppressing EWS::FLI1.
- To design and construct novel polyQ fusion proteins capable of sequestering EWS::FLI1 within Ewing sarcoma cells.
- To evaluate the impact of these polyQ fusions on EWS::FLI1 cellular availability and downstream gene expression.
Main Methods:
- A polyglutamine (polyQ) fusion strategy was employed using polyQ-expanded ataxin-7 (Atx793Q-N172) as a template.
- Three distinct polyQ fusion proteins (Atx793Q-N172-SYGQ1, Atx793Q-N172-SYGQ2, Atx793Q-N172-LCD) were designed and constructed.
- Experiments involved supernatant/pellet fractionation and immunofluorescence imaging in A673 Ewing sarcoma cells.
Main Results:
- The designed polyQ fusion proteins successfully co-precipitated and co-localized with endogenous EWS::FLI1 in A673 cells.
- PolyQ fusions sequestered EWS::FLI1 into insoluble aggregates, significantly reducing its soluble cellular availability.
- The Atx793Q-N172-LCD fusion notably altered EWS::FLI1 downstream gene expression, increasing P21 (CDKN1A) and decreasing c-Myc.
Conclusions:
- Engineered polyQ fusions effectively entrap endogenous EWS::FLI1 protein into aggregates, reducing its functional soluble fraction in Ewing sarcoma cells.
- This sequestration strategy presents a novel approach to inhibit the oncogenic activity of EWS::FLI1.
- The study offers a potential alternative therapeutic avenue for Ewing sarcoma and other cancers driven by similar oncogenic proteins.
Related Concept Videos
Abnormal Proliferation
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...

